Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;19(2):1356-1362.
doi: 10.3892/etm.2019.8339. Epub 2019 Dec 17.

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

Jujun Xue  1 , Cuiqing Wang  2 , Chengli Pan  1 , Haining Xing  3 , Lijuan Xu  4 , Xi Chen  5 , Xuping Wang  4 , Na Wang  6
Affiliations

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

Jujun Xue et al. Exp Ther Med. 2020 Feb.

Abstract

The aim of this study was to investigate the effect of dipeptidyl peptidase-4 (DPP-4) inhibitor on blood sugar level and cognitive ability in elderly patients with type 2 diabetes mellitus (T2DM) combined with post-stroke mild cognitive impairment (MCI). Thirty patients received DPP-4 inhibitor (study group), while another thirty received sulfonylurea (control group). Six months after treatment, markers regarding blood sugar were improved in both groups (all P<0.05) without intergroup differences (all P>0.05); scores regarding cognitive ability improved in the study group (both P<0.05) and were higher versus the control group (both P<0.01); the study group had higher Aβ1-42/Aβ1-40 value versus the pretreatment value (P<0.001), which differed from the control group (P<0.05); tumor necrosis factor-α and interleukin-6 concentrations decreased in both groups, while the study group had greater reductions; C-reactive protein value decreased after treatment in the study group (all P<0.05). Using DPP-4 inhibitor in elderly patients with T2DM combined with post-stroke MCI can lower blood sugar and improve cognitive ability. The mechanism may be associated with the improvement of Aβ gathering and reduction in inflammatory response.

Keywords: blood sugar; cognitive impairment; efficacy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Score of cognitive ability before and after treatment in the two groups. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment. **P<0.01, ***P<0.001 vs. the control group; #P<0.05 vs. before treatment.
Figure 2.
Figure 2.
Aβ1-42/Aβ1–40 level in plasma before and after treatment in the two groups. ***P<0.001 vs. the control group; ###P<0.001 vs. before treatment.
Figure 3.
Figure 3.
CRP, TNF-α, and IL-6 levels before and after treatment in the two groups. (A) CRP level before and after treatment, (B) TNF-α and IL-6 levels before and after treatment. CRP, C-reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6. ***P<0.001 vs. the control group; #P<0.05 vs. before treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgrad Med J. 2016;92:63–69. doi: 10.1136/postgradmedj-2015-133281. - DOI - PubMed
    1. Weuve J, Hebert LE, Scherr PA, Evans DA. Prevalence of Alzheimer disease in US states. Epidemiology. 2015;26:e4–e6. doi: 10.1097/EDE.0000000000000199. - DOI - PubMed
    1. Cumming TB, Marshall RS, Lazar RM. Stroke, cognitive deficits, and rehabilitation: still an incomplete picture. Int J Stroke. 2013;8:38–45. doi: 10.1111/j.1747-4949.2012.00972.x. - DOI - PubMed
    1. Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RM, Madhunapantula VS, Muthureddy Nataraj SK, Basavan D. Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology. 2013;72:291–300. doi: 10.1016/j.neuropharm.2013.04.008. - DOI - PubMed
    1. Le Couteur DG, Wahl D, Naismith SL. Comorbidity and vascular cognitive impairment-no dementia (VCI-ND) Age Ageing. 2017;46:705–707. doi: 10.1093/ageing/afx080. - DOI - PubMed